Respiratory

A March 2021 update on RECOVERY's initial colchicine results in hospitalised patients with COVID-19. It reports the lack of a mortality benefit announced at the time, distinguishes these patients from community cases and notes that the full paper was still awaited.

Dan Horner takes a detailed look at the February 2021 RECOVERY tocilizumab preprint. The appraisal examines reported survival benefits alongside patient selection, incomplete follow-up, absolute versus relative effects and the uncertainties that remained behind the optimistic headlines.

How do patients want clinicians to explain COVID-19 tests, uncertainty and the possibility of dying? In this February 2021 podcast, Rick Body speaks with patient representatives Graham Prestwich and Val Tate about communication through PPE and what matters to patients and families.

The first February 2021 report of RECOVERY's tocilizumab results, written as the announcement and preprint emerged. Simon Carley and Dan Horner outline the reported benefits in hospitalised patients with hypoxia and inflammation, while flagging the need for fuller appraisal and questions about immunosuppression.

Joke Van kerkhoven draws on emergency medicine and elite sport to explore leading yourself under pressure. Written during COVID-19, this practical reflection covers mindset, breathing, planning and recovery, with ways to prepare for difficult situations and learn from them afterwards.

A January 2021 appraisal of REMAP-CAP's early tocilizumab and sarilumab findings in critically ill patients with COVID-19. Dan Horner examines organ support and survival outcomes, strict eligibility criteria and the uncertainties that remained as the results moved rapidly into policy and public discussion.